• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Cost-effectiveness of lung cancer screening with CT estimated

byTomi Jun
November 5, 2014
in Chronic Disease, Imaging and Intervention, Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Screening for lung cancer with low-dose CT was found to cost ~$81,000 per quality-adjusted life-year (QALY) gained.

Evidence Rating Level: 2 (Good)

Study Rundown: The National Lung Screening Trial (NLST) has shown that screening for lung-cancer with low-dose CT can reduce lung cancer deaths, especially among those at high risk of lung cancer. This study compared the cost-effectiveness of screening with low-dose CT, screening with radiography, and no screening. The authors estimate that CT screening would cost about $1,600 more per person than no screening, and about $1,200 more per person than radiographic screening. These costs include the costs of screening as well as the costs of work-up and treatment of positive results.

The cost per life-year gained through screening was $52,000, while the cost per quality-adjusted life-year (QALY) gained was $81,000. However, these values depend on many of the assumptions made by the investigators and may not apply to implementation of this screening in other contexts.

Click to read the study, published today in NEJM

Relevant Reading: Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

In-Depth [cost-effectiveness analysis]: The NLST was a large trial that enrolled over 50,000 people in the US and randomized them to annual screening for lung cancer with either low-dose CT or chest radiography. Participants were between 55 and 74 years old with at least a 30 pack-year smoking history. This cost-effectiveness analysis of NLST data estimated the mean life-years, QALYs, costs per person, and incremental cost-effectiveness ratios (ICERs) of screening with low-dose CT, screening with radiography, and no screening. The Short Form Health Survey SF-36 was administered to 11,696 participants and the results were used to adjust life expectancy for quality of life. Estimates of costs per person included both direct medical costs (screening examination, diagnostic workup for positive screening results, and lung cancer treatment) and indirect costs (time and travel). The total costs per person were $3074, $1911, and $1443 for screening with CT, screening with radiography, and no screening, respectively. The ICERs for screening with CT compared to no screening were $52,000 per life-year gained and $81,000 per QALY gained.

RELATED REPORTS

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified

Image: PD/US Army

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: cancer screeningCT scanslung cancer
Previous Post

Modified embryonic stem cells may prolong survival of surgical grafts

Next Post

Double-opposing Z-plasty may improve cleft palate outcomes

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

July 1, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

June 14, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Next Post
Double-opposing Z-plasty may improve cleft palate outcomes

Double-opposing Z-plasty may improve cleft palate outcomes

Fatty liver disease may independently predict high-risk coronary disease

Fatty liver disease may independently predict high-risk coronary disease

Childhood migraine associated with infantile colic

Shift work impacts cognition, but likely not permanently

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.